Anteris Technologies Global Corp. reported a significant decline in financial performance for the third quarter of 2025, with net sales of $429,769, a decrease of 73% compared to $1.6 million in the same period last year. For the nine months ending September 30, 2025, the company generated $1.6 million in revenue, down 26% from $2.2 million in the prior year. The decrease in revenue is attributed to the expiration of a Transition Services Agreement with LeMaitre Vascular, which previously included sales of CardioCel™ and VascuCel™ products, partially offset by increased demand for other tissue products.

The company's operating loss for the third quarter was $22.3 million, an increase of 8% from a loss of $20.6 million in the same quarter of 2024. For the nine-month period, the operating loss rose to $64.9 million, up 14% from $56.9 million in the previous year. Research and development expenses increased by 21% to $16.8 million for the quarter, driven by costs associated with scaling manufacturing capabilities and preparatory activities for the PARADIGM Trial, which aims to evaluate the DurAVR® THV System. Selling, general, and administrative expenses decreased by 17% to $5.8 million, reflecting reduced share-based payment expenses and lower travel costs.

Anteris has made strategic advancements in its operations, including the initiation of the PARADIGM Trial, which received regulatory clearance in Denmark in October 2025. The trial is designed to support a future Premarket Approval application for the DurAVR® THV System in the U.S. and CE Mark approval in Europe. The company also completed a private placement in October and November 2025, generating approximately $25.2 million in gross proceeds, which will be reflected in future financial statements.

As of September 30, 2025, Anteris reported cash and cash equivalents of $9.1 million, a significant decrease from $70.5 million at the end of 2024. The company has indicated that it will require additional capital to fund ongoing operations and achieve its long-term goals, including the completion of the PARADIGM Trial and commercialization of its products. The outlook remains cautious, with expectations of continued losses until significant revenue generation begins post-regulatory approvals.

About Anteris Technologies Global Corp.

Anteris Technologies is a medical device company specializing in innovative transcatheter aortic valve replacement (TAVR) systems. Its flagship product, DurAVR, features a biomimetic, single-piece design with proprietary ADAPT tissue technology for enhanced durability and hemodynamics. The company targets the global cardiovascular market, focusing on treating aortic stenosis with minimally invasive solutions that aim to improve patient outcomes and valve longevity.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.